Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Both
Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Trial Information
Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia
Inclusion Criteria:
- Age ≥ 18 years
- High Risk or Intermediate 2 MDS (IPSS)
- AML-MD (WHO classification)
- Treatment with minimum three to six cycles of Azacitidine
- Informed consent form signed
Exclusion Criteria:
- Treatment with others chemotherapies alone or in association
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Authority:
France: French Data Protection Authority
Study ID:
10-PP-10
NCT ID:
NCT01210274
Start Date:
September 2010
Completion Date:
September 2013
Related Keywords:
- Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
|---|
